Celecoxib-Acetaminophen Coated Tablet Stability via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The combination of celecoxib and acetaminophen poses technical challenges due to their differing rheological and solubility characteristics, leading to stability issues, delayed dissolution, and potential pharmacokinetic interactions.
Innovation Solution
A pharmaceutical composition comprising celecoxib and acetaminophen in the form of an immediate release coated tablet, manufactured through a process that involves mixing the active ingredients with humectants, binders, disintegrants, and lubricants, followed by granulation, drying, and compression to ensure stability and effective absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If celecoxib and acetaminophen are combined in a pharmaceutical composition, then the analgesic effect is enhanced, but stability issues and delayed dissolution occur due to differing rheological and solubility characteristics
Solution Approach 1:
The patent divides the formulation into separate functional layers: celecoxib is incorporated into a hydrophobic matrix (polylactide-co-glycolide or polyethylene oxide) while acetaminophen is placed in a hydrophilic matrix (hydroxypropyl methylcellulose). This spatial segmentation prevents direct contact between the two active ingredients, eliminating chemical interactions and stability issues while maintaining both analgesic effects.
Solution Approach 2:
The patent introduces excipients as intermediary substances that mediate between celecoxib and acetaminophen. Specifically, hydrophobic excipients (polylactide-co-glycolide, polyethylene oxide) interact with celecoxib to form a stable hydrophobic complex, while hydrophilic excipients (hydroxypropyl methylcellulose, starch) interact with acetaminophen. These intermediaries prevent direct harmful interactions between the two active ingredients while allowing both to function effectively.
2Reliability
If celecoxib and acetaminophen are combined, then synergistic analgesic effect is achieved, but dissolution is delayed due to differing solubility characteristics
Solution Approach 1:
The patent segments the formulation into distinct hydrophobic and hydrophilic domains. Celecoxib, being hydrophobic, is dissolved in a hydrophobic matrix that releases it slowly, while acetaminophen, being hydrophilic, is dissolved in a hydrophilic matrix that releases it rapidly. This segmentation allows each drug to dissolve at its optimal rate without being constrained by the other drug's solubility characteristics, thereby maintaining synergistic effect while avoiding dissolution delay.
Solution Approach 2:
The patent applies local quality by creating different micro-environments within the tablet: a hydrophobic micro-environment for celecoxib and a hydrophilic micro-environment for acetaminophen. Each local region has properties optimized for its specific drug, allowing celecoxib to be released slowly from the hydrophobic region while acetaminophen is released rapidly from the hydrophilic region, thus achieving both synergistic effect and rapid overall dissolution.
3Reliability
If celecoxib is used in high concentration for effective pain relief, then analgesic effect is improved, but adverse effects increase
Solution Approach 1:
The patent segments the dose delivery by separating celecoxib and acetaminophen into different matrices. This allows the celecoxib component to be released in a controlled, slower manner from the hydrophobic matrix, reducing peak plasma concentrations and associated adverse effects, while the acetaminophen component provides rapid analgesic effect from the hydrophilic matrix. The segmentation enables effective pain relief through both drugs working together at lower individual doses.
Solution Approach 2:
The patent merges the therapeutic effects of celecoxib and acetaminophen into a single tablet formulation where both drugs work synergistically. By combining them in a way that maintains their individual benefits while controlling their release profiles, the formulation achieves effective pain relief at lower doses of each drug, thereby reducing adverse effects compared to high-dose monotherapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process results in a stable pharmaceutical composition with improved stability, rapid dissolution, and enhanced bioavailability, effectively addressing the challenges of combining celecoxib and acetaminophen while minimizing adverse effects.
Implementation Method 1
moistening with purified water and granulating the mixture
Implementation Method 2
drying the granulate obtained in the previous step until reaching a humidity between approximately 1.8% and 2.0%
Data Source
AI summary
It is described and claimed a pharmaceutical composition comprising celecoxib and acetaminophen as active ingredients, wherein the pharmaceutical composition is an immediate release coated tablet. The pharmaceutical composition is particularly stable and allows the oral administration in a single dosage unit of two active ingredients. It is further provided a process for manufacturing the pharmaceutical composition, as well as the use of said pharmaceutical composition for the treatment of pain, it provides analgesia and a reduction of adverse effects.